Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of ($1.71) per share for the quarter.
Cadrenal Therapeutics Trading Up 0.9 %
CVKD stock opened at $16.85 on Friday. The company’s 50 day moving average is $18.07 and its 200 day moving average is $14.74. The stock has a market cap of $30.04 million, a price-to-earnings ratio of -2.52 and a beta of 1.40. Cadrenal Therapeutics has a 1-year low of $5.40 and a 1-year high of $22.90.
Analyst Upgrades and Downgrades
Separately, HC Wainwright upped their price objective on shares of Cadrenal Therapeutics from $3.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, November 11th.
Cadrenal Therapeutics Company Profile
Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
See Also
- Five stocks we like better than Cadrenal Therapeutics
- How to Evaluate a Stock Before Buying
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- Comparing and Trading High PE Ratio Stocks
- 3 Stocks to Buy While Others Stay on the Sidelines
- P/E Ratio Calculation: How to Assess Stocks
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
